| A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC) (NCT05429320) | Memorial Sloan Kettering Cancer Center | 2022-06-15 |
| Study of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLC (NCT05265650) | Clinica Universidad de Navarra, Universidad de Navarra | 2022-06-13 |
| Bevacizumab Plus Nab-paclitaxel and Platinum for Immunotherapy-treated Non-squamous Non-small Cell Lung Cancer (NCT05407155) | Fudan University | 2022-06-09 |
| A Study to Investigate LYL797 in Adults With Solid Tumors (NCT05274451) | Lyell Immunopharma, Inc. | 2022-03-29 |
| Radiotherapy Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of NSCLC Patients With Symptomatic Brain Metastases (NCT05638425) | Xiangya Hospital of Central South University | 2021-12-31 |
| Camrelizumab Combination With SBRT and Concurrent Chemotherapy Treated Stage IV Oligometastatic Non-small Cell Lung Cancer (NCT05472467) | Sichuan Cancer Hospital and Research Institute | 2021-12-21 |
| Fecal Microbial Transplantation Non-Small Cell Lung Cancer and Melanoma (NCT04951583) | Centre hospitalier de l'Université de Montréal (CHUM) | 2021-11-16 |
| Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer (NCT04994795) | Sophia Genetics SAS | 2021-08-21 |
| Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients (NCT04923945) | Hutchison Medipharma Limited | 2021-08-19 |
| An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE) (NCT04563338) | University Health Network, Toronto | 2021-06-04 |
| Lung Cancer Cryo-Activation as a Novel Approach to Augment Immunotherapy Efficacy (CRYOVATE) (NCT04793815) | Centre hospitalier de l'Université de Montréal (CHUM) | 2021-05-01 |
| Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination (NCT04868877) | Merus B.V. | 2021-04-28 |
| Phase II Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer (NCT04836728) | Tianjin Medical University Cancer Institute and Hospital | 2021-03-31 |
| Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS) (NCT04621188) | Intergroupe Francophone de Cancerologie Thoracique | 2021-03-19 |
| HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer (NCT04619004) | Daiichi Sankyo | 2021-02-02 |
| Dacomitinib in Lung Cancer With Uncommon EGFR Mutations (NCT04504071) | Shanghai Chest Hospital | 2020-12-08 |
| Almonertinib With Chemotherapy in mEGFR NSCLC (NCT04646824) | Tianjin Medical University Cancer Institute and Hospital | 2020-11-19 |
| Study to Investigate DRP-104 in Adults With Advanced Solid Tumors (NCT04471415) | Dracen Pharmaceuticals, Inc. | 2020-08-31 |
| Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04) (NCT04394624) | Sanofi | 2020-08-31 |
| Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion. (NCT04749602) | Kidney Cancer Research Bureau | 2020-08-10 |
| Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer (NCT04111705) | Intergroupe Francophone de Cancerologie Thoracique | 2020-08-05 |
| Pharmacokinetic Characteristics, Safety, Tolerability and Immunogenicity of LY01008 and Avastin in Healthy Chinese Male Subjects (NCT05110118) | Shandong Boan Biotechnology Co., Ltd | 2020-08-04 |
| Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation (NCT04233021) | Intergroupe Francophone de Cancerologie Thoracique | 2020-07-16 |
| Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC (NCT04163432) | University of Utah | 2020-06-18 |
| Low-dose Gemcitabine Combined With Nivolumab for Second-line and Above Line Treatment of NSCLC (NCT04331626) | Henan Cancer Hospital | 2020-04-01 |
| SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients (NCT04154956) | Sanofi | 2020-02-06 |
| Immunological Profile Changes In Patients With Advanced Non-Small Cell Lung Cancer (NCT04187768) | Indiana University | 2019-11-26 |
| Thyroid Dysfunction and Nivolumab Reponse in NSCLC (NCT04470440) | University Hospital, Brest | 2019-10-22 |
| Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC (NCT04069936) | WindMIL Therapeutics | 2019-10-15 |
| Evolution of the Physical Condition in Treated Cancer Patients (NCT03956641) | Centre Paul Strauss | 2019-09-17 |
| MIDRIX4-LUNG Dendritic Cell Vaccine in Patients With Metastatic Non-small Cell Lung Cancer (NCT04082182) | University Hospital, Ghent | 2019-08-26 |
| Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy (NCT03977194) | Intergroupe Francophone de Cancerologie Thoracique | 2019-07-23 |
| Evaluation of the Quality of Life of Patients With Metastatic Non-small Cell Lung Cancer With Supplementary Therapy With IGEN-0206 (NCT04009122) | Igen BioLab SLU | 2019-06-11 |
| Her2-positive Lung Cancer Treated With Dedicated Drug (NCT03845270) | Intergroupe Francophone de Cancerologie Thoracique | 2019-05-17 |
| Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer (NCT03907852) | TCR2 Therapeutics | 2019-04-15 |
| A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer (NCT03846310) | Arcus Biosciences, Inc. | 2019-04-01 |
| Temozolomide Combine With Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost for Non Small Cell Lung Cancer Brain Metastases (NCT03732482) | Taizhou Hospital | 2019-03-01 |
| Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLC (NCT03732274) | MedPacto, Inc. | 2019-02-11 |
| Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC (NCT03611738) | H. Lee Moffitt Cancer Center and Research Institute | 2019-02-01 |
| Efficacy of Treatment Sequences in Patients With Non-small Cell Lung Cancer Receiving Lorlatinib (NCT03727477) | Intergroupe Francophone de Cancerologie Thoracique | 2019-02-01 |
| Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac) (NCT03715985) | Herlev Hospital | 2019-01-28 |
| Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung (NCT03808662) | Memorial Sloan Kettering Cancer Center | 2019-01-16 |
| TKI Followed by Thoracic Radiotherapy for Stage IV EGFR Mutant NSCLC (NCT03916913) | Chinese Academy of Medical Sciences | 2019-01-01 |
| ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer (NCT03445000) | ETOP IBCSG Partners Foundation | 2018-11-06 |
| Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr (NCT03469960) | Intergroupe Francophone de Cancerologie Thoracique | 2018-05-02 |
| Registry of Guardant360® Use and Outcomes In People With Advanced Cancer (NCT03477474) | Guardant Health, Inc. | 2018-04-06 |
| Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer (NCT03377023) | H. Lee Moffitt Cancer Center and Research Institute | 2018-02-02 |
| A Study of ASN007 in Patients With Advanced Solid Tumors (NCT03415126) | Asana BioSciences | 2018-01-19 |
| A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC) (NCT03353675) | Transgene | 2018-01-05 |
| A Study to Evaluate Effectiveness and Safety of Tyrosine Kinase Inhibitors (NCT03424980) | Tang-Du Hospital | 2017-12-31 |
| First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b (NCT06517433) | Mersana Therapeutics | 2017-12-12 |
| First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b (NCT03319628) | Mersana Therapeutics | 2017-12-12 |
| Survival Prolongation by Rationale Innovative Genomics (NCT03386929) | Worldwide Innovative Network Association | 2017-11-29 |
| Verification of Novel Survival Prediction Algorithm for Patients With NSCLC Spinal Metastasis (NCT03363685) | Ruijin Hospital | 2017-11-01 |
| Immunotherapy by Nivolumab for HIV+ Patients (NCT03304093) | Intergroupe Francophone de Cancerologie Thoracique | 2017-10-19 |
| Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 (NCT03307785) | Tesaro, Inc. | 2017-10-12 |
| Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632) (NCT03168464) | Weill Medical College of Cornell University | 2017-10-09 |
| Effectiveness and Safety of Adding Bevacizumab to First Line Chemotherapy in Lung Cancer Patients With Stable Disease (NCT03240549) | Beijing Hospital | 2017-08-01 |
| CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab (NCT03123783) | Apexigen America, Inc. | 2017-07-10 |
| Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases (NCT02978404) | Centre hospitalier de l'Université de Montréal (CHUM) | 2017-06-02 |
| Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M (NCT03133546) | ETOP IBCSG Partners Foundation | 2017-05-31 |
| Cancer Panel From Blood of Lung Cancer Patients (NCT03235765) | Seoul National University Hospital | 2017-03-10 |
| Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK (NCT02959619) | Betta Pharmaceuticals Co., Ltd. | 2017-03-06 |
| Hypofractionated Radiation Therapy to Improve Immunotherapy Response in Non-Small Cell Lung Cancer (NCT03035890) | West Virginia University | 2017-01-23 |
| Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung Cancer (NCT06207292) | Radiotherapy Oncology Centre "Santa Maria" Hospital | 2016-12-01 |
| A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer (NCT02967133) | Alliance Foundation Trials, LLC. | 2016-12-01 |
| High-activity Natural Killer Immunotherapy for Small Metastases of Non-small Cell Lung Cancer (NCT03007875) | Fuda Cancer Hospital, Guangzhou | 2016-12-01 |
| A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer (NCT02922764) | Inspirna, Inc. | 2016-11-01 |
| ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC (NCT02946216) | First People's Hospital of Hangzhou | 2016-11-01 |
| Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) (NCT02812667) | Lyudmila Bazhenova, M.D. | 2016-08-29 |
| Combination of Cryosurgery and NK Immunotherapy for Advanced Non-Small Cell Lung Cancer (NCT02843815) | Fuda Cancer Hospital, Guangzhou | 2016-07-01 |
| EGFR Mutations on ctDNA in Patients With Advanced NSCLC (NCT02623257) | First People's Hospital of Hangzhou | 2016-01-01 |
| Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients (NCT02622581) | AIO-Studien-gGmbH | 2015-12-01 |
| A Study of LY3023414 and Necitumumab in Squamous Lung Cancer (NCT02443337) | Eli Lilly and Company | 2015-07-01 |
| T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure (NCT02418234) | First People's Hospital of Hangzhou | 2015-03-01 |
| Safety Study of SEA-CD40 in Cancer Patients (NCT02376699) | Seagen Inc. | 2015-02-28 |
| Study to Evaluate Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients (NCT02228421) | PeriPharm | 2015-02-01 |
| A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC (NCT02314364) | Massachusetts General Hospital | 2014-12-01 |
| Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC (NCT02299765) | Sichuan University | 2014-12-01 |
| SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients (NCT02117167) | UNICANCER | 2014-04-23 |
| Exercise Intervention During Chemotherapy in Advanced Lung Cancer Patients (NCT03334071) | University Hospital Southampton NHS Foundation Trust | 2014-04-04 |
| Study to Evaluate Resistance Mechanisms and Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients (NCT02041468) | Jewish General Hospital | 2014-01-01 |
| Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Brain Metastases (NCT02162537) | Centre Hospitalier Intercommunal Creteil | 2013-12-01 |
| Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer (NCT01999673) | Peregrine Pharmaceuticals | 2013-12-01 |
| Metformin and Carbohydrate Restriction With Platinum Based Chemotherapy In Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC) (NCT02019979) | Beth Israel Medical Center | 2013-12-01 |
| Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer (NCT01966003) | Amgen | 2013-11-11 |
| PET/CT Scan as a Tool to Rationalize the Treatment of of Advanced NSCLC Patients Undergoing First Chemotherapy (NCT02035683) | National Cancer Institute, Naples | 2013-10-01 |
| A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC (NCT01798485) | Synta Pharmaceuticals Corp. | 2013-04-01 |
| A Randomized Phase II Study of SUBATM-itraconazole in Patients With Untreated Squamous NSCLC. (NCT01752023) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2013-03-01 |
| Re-introduction of Pemetrexed and Cisplatin With Prolonged Angiogenic Blocking by Bevacizumab in Advanced Lung Cancer. (NCT01705184) | Intergroupe Francophone de Cancerologie Thoracique | 2012-12-01 |
| A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer (NCT01703091) | Eli Lilly and Company | 2012-12-01 |
| Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC (NCT01848613) | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 2012-10-01 |
| Efficacy Study of Vx001 Vaccine in NSCLC Patients (NCT01935154) | Vaxon Biotech | 2012-08-01 |
| MILES-4: Study Comparing Gemcitabine and Pemetrexed, With or Without Cisplatin, in Patients With Nonsquamous Lung Cancer (NCT01656551) | National Cancer Institute, Naples | 2012-08-01 |
| 5-Fluorouracil Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lung Cancer (NCT01658813) | Western Regional Medical Center | 2012-07-01 |
| A Study of Home Administration of Pemetrexed as Maintenance Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (NCT01473563) | Eli Lilly and Company | 2011-12-01 |
| Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer (NCT01471964) | Fox Chase Cancer Center | 2011-10-20 |
| A Prospective Observational Study Evaluating c-MET Expression and EGFR Gene Mutation Correlation With Erlotinib Response (NCT01523340) | Chonnam National University Hospital | 2011-09-01 |
| Feasibility of the Research for Mutation of K-ras and EGFR in CTCs From Metastatic Non Small Cells Bronchial Carcinomas (NCT01380795) | Centre Georges Francois Leclerc | 2011-03-09 |
| MILES-3: Cisplatin in Combination With Gemcitabine for Elderly Patients With Lung Cancer (NCT01405586) | National Cancer Institute, Naples | 2011-03-01 |